Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX, 77030, USA.
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Breast Cancer Res Treat. 2021 Apr;186(2):273-283. doi: 10.1007/s10549-020-06092-5. Epub 2021 Jan 21.
The purpose of this review is to clarify the association of body composition with breast cancer risk and treatment, including physiological mechanisms, and to elucidate strategies for overcoming unfavorable body composition changes that relate to breast cancer progression.
We have summarized updated knowledge regarding the mechanism of the negative association of altered body composition with breast cancer risk and treatment. We also review strategies for reversing unfavorable body composition based on the latest clinical trial results.
Body composition changes in patients with breast cancer typically occur during menopause or as a result of chemotherapy or endocrine therapy. Dysfunction of visceral adipose tissue (VAT) in the setting of obesity underlies insulin resistance and chronic inflammation, which can lead to breast cancer development and progression. Insulin resistance and chronic inflammation are also observed in patients with breast cancer who have sarcopenia or sarcopenic obesity. Nutritional support and a personalized exercise program are the fundamental interventions for reversing unfavorable body composition. Other interventions that have been explored in specific situations include metformin, testosterone, emerging agents that directly target the adipocyte microenvironment, and bariatric surgery.
A better understanding of the biology of body composition phenotypes is key to determining the best intervention program for patients with breast cancer.
本综述旨在阐明体成分与乳腺癌风险和治疗的关联,包括生理机制,并阐明克服与乳腺癌进展相关的不利体成分变化的策略。
我们总结了关于改变的体成分与乳腺癌风险和治疗呈负相关的机制的最新知识。我们还根据最新的临床试验结果,回顾了逆转不利体成分的策略。
乳腺癌患者的体成分变化通常发生在绝经期间或由于化疗或内分泌治疗。肥胖情况下内脏脂肪组织(VAT)的功能障碍导致胰岛素抵抗和慢性炎症,从而导致乳腺癌的发生和发展。患有肌肉减少症或肌肉减少性肥胖症的乳腺癌患者也存在胰岛素抵抗和慢性炎症。营养支持和个性化运动方案是逆转不利体成分的基本干预措施。在特定情况下还探索了其他干预措施,包括二甲双胍、睾酮、直接靶向脂肪细胞微环境的新兴药物以及减重手术。
更好地了解体成分表型的生物学特性是确定乳腺癌患者最佳干预方案的关键。